Drug
Epcoritamab
Epcoritamab: highest development phase Phase 3, developed by Genmab. 14 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Genmab
Trials
| Drug | Phase | Indication |
|---|---|---|
| Epcoritamab NCT05578976 | Phase 3 | Diffuse Large B-Cell Lymphoma |
| Epcoritamab NCT04628494 | Phase 3 | Diffuse Large B-cell Lymphoma |
| Epcoritamab NCT07226752 | Phase 3 | Diffuse Large B-Cell Lymphoma |
| Epcoritamab NCT07819214 | Phase 2 | CLL |
| Epcoritamab NCT06510491 | Phase 2 | Waldenstrom Macroglobulinemia |
| Epcoritamab NCT07030699 | Phase 2 | Lymphoma |
| Epcoritamab NCT06796998 | Phase 2 | Marginal Zone Lymphoma |
| Epcoritamab NCT06458439 | Phase 2 | Lymphoma, Non-Hodgkin |
| Epcoritamab NCT06510361 | Phase 2 | Lymphoma |
| Epcoritamab NCT05201248 | Phase 1/2 | B-Cell Non-Hodgkin Lymphoma |
| Epcoritamab NCT03625037 | Phase 1/2 | DLBCL |
| Epcoritamab NCT04623541 | Phase 1/2 | Relapsed/Refractory Chronic Lymphocytic Leukemia |
| Epcoritamab (monotherapy) NCT04542824 | Phase 1/2 | Diffuse Large B Cell Lymphoma |
| Epcoritamab NCT05206357 | Phase 1 | Non-hodgkin Lymphoma |
Latest
No recent events.
Follow Epcoritamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.